Back to results
US 11,519,911 B2Granted
ALX receptor ligands define a biochemical endotype for inflammation-based diseases
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsBruce Levy, Charles N. Serhan
Life of this patent
Estimating the term…
Abstract
A method to determine the severity of a disease of chronic inflammation in a patient, comprising the steps of (1) collection or preparation of a bodily fluid, tissue or lavage and (2) measurement of ALX receptor ligands or ALX receptor expression in the fluid, tissue, or lavage, wherein the level of ALX receptor ligands predicts a clinical outcome or choice of treatment modality, is disclosed.
Claims5
A method of mitigating or inhibiting asthma in a patient in need thereof comprising:
- (a) measuring ALX/FPR2 receptor expression and optionally ligands serum amyloid A (SAA) and lipoxin A4 (LXA4), and analogs or mimetics thereof in a fluid, tissue, or lavage;
- (b) comparing the expression of ALX/FPR2 to healthy control;
- and
- (c) administering LXA4 or analogs thereof in patients having elevated ALX/FPR2 and asthma.
1 more element
Dependencies are inferred from the claim text.